Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Long-term Extension Study of Ustekinumab in Pediatric Participants
2020-004457-76Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ustekinumab in Crohn's disease and Immune-mediated pediatric conditions, sponsored by Janssen Pharmaceutical. Primary endpoint: Safety and tolerability (long-term). Started Aug 2021; status: active.
02
Drugs
ustekinumab
03
Conditions
Crohn's diseaseImmune-mediated pediatric conditions
Beyond the preview
Go deeper on 2020-004457-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004457-76.